Viveve Announces $6 Million Private Placement of Common Stock Led by Leading Healthcare-Focused Institutional Investors
SUNNYVALE, CA -- (Marketwired) -- 11/20/15 -- Viveve Medical, Inc. ("Viveve") (OTCQB: VIVMF), a company focused on women's health, today announced that it has entered into definitive agreements for the sale of $6 million of its common stock in a private placement. Under the terms of the agreements, Viveve has agreed to sell approximately 8.6 million shares at a per share purchase price of $0.70.
Viveve plans to use the net proceeds from the offering to support the commercial launch of the Viveve® System in the 46 countries where it is now available through select distributors. The closing of the private placement is anticipated to occur on or about November 24, 2015, subject to the satisfaction of customary closing conditions.
"This financing strengthens our balance sheet and will continue to support the commercial launch of the Viveve® System in the regions where we have regulatory approvals," said Patricia Scheller, Chief Executive Officer of Viveve.
"We're pleased to have such strong support from existing investors, including participation from Stonepine Capital, RTW Investments, Alta Bioequities, Wexford Capital LP, Manchester Management Company, LLC, as well as other investors and company management," said Scott Durbin, Viveve's Chief Financial Officer.
Sterne Agee CRT acted as lead placement agent and Maxim Group LLC acted as co-placement agent for the transaction.
The securities offered in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Viveve has agreed to file a registration statement covering the resale of the common stock issued in the private placement. The securities were offered only to accredited investors.
This release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state.
Further details of the placement will be described in a Current Report on Form 8-K to be filed by Viveve with the Securities and Exchange Commission.
Viveve, Inc., the operating subsidiary of Viveve Medical, Inc., is a women's health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The company's lead product, the globally patented Viveve® System, is a non-surgical, non-ablative medical device that remodels collagen and restores tissue with only one treatment session. The Viveve System treats the condition of vaginal laxity, which is the result of the over-stretching of tissue during childbirth that can result in a decrease in physical sensation and sexual satisfaction. Physician surveys indicate that vaginal laxity is the number one post-delivery physical change for women, being more prevalent than weight gain, urinary incontinence or stretch marks. The Viveve Treatment uses patented, reverse-thermal gradient radiofrequency technology to tighten vaginal tissue in one 30-minute out-patient treatment in a physician's office. The Viveve System has received regulatory approval in Europe, Canada and Hong Kong and is available through physician import license in Japan. It is currently not available for sale in the U.S. For more information, please visit Viveve's website at www.viveve.com.
Safe Harbor Statement
All statements in this press release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are to be detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Viveve is a registered trademark of Viveve, Inc.
Amato and Partners, LLC
Investor Relations Counsel
90 Park Avenue. 17th Floor
New York, NY 10016
Source: Viveve Medical, Inc.
Released November 20, 2015